Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.
Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Dünnebacke J, Belzl N, Augustin D, Kates RE, Harbeck N; West German Study Group.
Nitz U, et al. Among authors: kates re.
Ann Oncol. 2014 Jan;25(1):75-80. doi: 10.1093/annonc/mdt505.
Ann Oncol. 2014.
PMID: 24356620
Free article.
Clinical Trial.